Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical Practice Guidelines – Acute Myeloid Leukaemia in Adult Patients

Published in 2020 – Ann Oncol (2020); 31(0): 0-0.
Authors: M. Heuser, Y. Ofran, N. Boissel, S. Brunet Mauri, C. Craddock, J. Janssen, A. Wierzbowska & C. Buske, on behalf of the ESMO Guidelines Committee

Highlights:
  • This updated ESMO Clinical Practice Guideline provides key recommendations on the management of acute myeloid leukaemia (AML) including acute promyelocytic leukaemia (APL) 
  • Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe  
  • A summary of recommendations is provided, including levels of evidence and grades of recommendation where applicable 
  • Recommendations take the approval status of AML drugs in Europe into account until the year 2019
  • Detailed guidance on diagnosis, classification, response assessment, treatment and follow up is provided for adults with AML and APL

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.